title: Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells.
abstract: Highly active antiretroviral therapy (HAART) is often associated with endothelial dysfunction and cardiovascular complications. In this study, we determined whether HIV non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) could increase endothelial permeability. Human coronary artery endothelial cells (HCAECs) were treated with EFV (1, 5 and 10 microg/ml) and endothelial permeability was determined by a transwell system with a fluorescence-labeled dextran tracer. HCAECs treated with EFV showed a significant increase of endothelial permeability in a concentration-dependent manner. With real time PCR analysis, EFV significantly reduced the mRNA levels of tight junction proteins claudin-1, occludin, zonula occluden-1 and junctional adhesion molecule-1 compared with controls (P<0.05). Protein levels of these tight junction molecules were also reduced substantially in the EFV-treated cells by western blot and flow cytometry analyses. In addition, EFV also increased superoxide anion production with dihydroethidium and cellular glutathione assays, while it decreased mitochondrial membrane potential with JC-staining. Antioxidants (ginkgolide B and MnTBAP) effectively blocked EFV-induced endothelial permeability and mitochondrial dysfunction. Furthermore, EFV increased the phosphorylation of MAPK JNK and IkappaBalpha, thereby increasing NFkappaB translocation to the nucleus. Chemical JNK inhibitor and dominant negative mutant JNK and IkappaBalpha adenoviruses effectively blocked the effects of EFV on HCAECs. Thus, EFV increases endothelial permeability which may be due to the decrease of tight junction proteins and the increase of superoxide anion. JNK and NFkappaB activation may be directly involved in the signal transduction pathway of EFV action in HCAECs.
authors.affiliation: Molecular Surgeon Research Center, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
authors.forename: Md Saha
authors.initials: MS
authors.lastname: Jamaluddin
authors.forename: Peter H
authors.initials: PH
authors.lastname: Lin
authors.forename: Qizhi
authors.initials: Q
authors.lastname: Yao
authors.forename: Changyi
authors.initials: C
authors.lastname: Chen
mesh_terms: D000480:Alkynes; D048588:Benzoxazines / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects*; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000166:cytology* / Q000187:drug effects*; D003521:Cyclopropanes; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz
references.citation: Dig Dis Sci. 2008 Apr;53(4):1054-62
references.pmid: 17934819
references.citation: Vascul Pharmacol. 2002 Nov;39(4-5):247-56
references.pmid: 12747964
references.citation: J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9
references.pmid: 15247553
references.citation: J Biol Chem. 2003 Feb 7;278(6):4194-204
references.pmid: 12401783
references.citation: Clin Infect Dis. 2003 Dec 15;37(12):1711-7
references.pmid: 14689356
references.citation: Cell. 1994 Jan 28;76(2):301-14
references.pmid: 7507411
references.citation: Atherosclerosis. 2008 Feb;196(2):720-6
references.pmid: 17275008
references.citation: Hypertension. 2007 Apr;49(4):717-27
references.pmid: 17296874
references.citation: Am J Physiol. 1997 Jul;273(1 Pt 2):H286-94
references.pmid: 9249502
references.citation: Cancer Res. 2002 Sep 15;62(18):5381-5
references.pmid: 12235011
references.citation: Lancet. 2003 Jul 5;362(9377):22-9
references.pmid: 12853195
references.citation: Circ Res. 2008 Feb 15;102(3):347-55
references.pmid: 18048770
references.citation: Arch Pharm Res. 2006 Dec;29(12):1074-9
references.pmid: 17225453
references.citation: Atherosclerosis. 2003 Jun;168(2):367-73
references.pmid: 12801621
references.citation: J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):493-9
references.pmid: 17245228
references.citation: Biochem Biophys Res Commun. 2005 Sep 30;335(3):874-82
references.pmid: 16105660
references.citation: World J Surg. 2007 Apr;31(4):632-43
references.pmid: 17372667
references.citation: Clin Infect Dis. 2007 Jul 15;45(2):263-6
references.pmid: 17578790
references.citation: Am J Physiol. 1998 May;274(5):H1776-84
references.pmid: 9612390
references.citation: Am J Pathol. 2007 Jul;171(1):304-14
references.pmid: 17591975
references.citation: Am J Physiol. 1986 May;250(5 Pt 2):H822-7
references.pmid: 3010744
references.citation: Arterioscler Thromb Vasc Biol. 2008 May;28(5):906-12
references.pmid: 18309109
references.citation: Surgery. 2005 Sep;138(3):464-73
references.pmid: 16213900
references.citation: Surgery. 2006 Aug;140(2):243-51
references.pmid: 16904976
references.citation: Cardiovasc Toxicol. 2004;4(3):287-302
references.pmid: 15470276
references.citation: Heart. 2004 May;90(5):486-7
references.pmid: 15084535